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Rebamipide prevents peripheral arthritis 
and intestinal inflammation by reciprocally 
regulating Th17/Treg cell imbalance in mice 
with curdlan-induced spondyloarthritis
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Abstract 
Background: Spondyloarthritis (SpA) usually manifests as arthritis of the axial and peripheral joints but can also result 
in extra‑articular manifestations such as inflammatory bowel disease. Proinflammatory cytokine interleukin‑17 (IL‑17) 
plays a crucial role in the pathogenesis of SpA. Rebamipide inhibits signal transducer and activator of transcription 
3 that controls IL‑17 production and Th17 cell differentiation. This study examined the effect of rebamipide on SpA 
development.
Methods: SKG ZAP‑70W163C mice were immunized with curdlan to induce SpA features. The mice were then intra‑
peritoneally injected with rebamipide or vehicle 3 times a week for 14 weeks and their clinical scores were evaluated. 
Histological scores of the paw and spine and the length of the gut were measured at sacrifice. Immunohistochemi‑
cal staining of IL‑17 and tumor necrosis factor‑α (TNF‑α) was performed using tissue samples isolated from the axial 
joints, peripheral joints, and gut. Spleen tissue samples were isolated from both rebamipide‑ or vehicle‑treated mice 
with SpA at 14 weeks after curdlan injection to determine the effect of rebamipide on Th17 and regulatory T (Treg) 
cell differentiation.
Results: Rebamipide decreased the clinical and histological scores of the peripheral joints. The total length of the 
gut was preserved in rebamipide‑treated mice. IL‑17 and TNF‑α expression in the spine, peripheral joints, and gut was 
lower in rebamipide‑treated mice than in control mice. Th17 cell differentiation was suppressed whereas Treg cell dif‑
ferentiation was upregulated in the spleen of rebamipide‑treated mice.
Conclusion: Rebamipide exerted beneficial effects in mice with SpA by preventing peripheral arthritis and intestinal 
inflammation and by regulating Th17/Treg cell imbalance, suggesting that it can be used as a potential therapeutic 
agent for treating arthritis to SpA patients.
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Background
Spondyloarthritis (SpA) is a chronic immune-mediated 
inflammatory arthritis that usually accompanies sacro-
iliitis and spondylodiscitis. SpA can cause inflammation 
of the peripheral joints and extra-articular organs such 
as the intestine, eye, and skin. SpA can be classified into 
ankylosing spondylitis (AS), psoriatic arthritis (PsA), 
reactive arthritis, arthritis associated with inflammatory 
bowel disease, and undifferentiated SpA based on its 
clinical manifestations [1].
Recent studies have shown that interleukin-23 (IL-23) 
and IL-17 play a crucial role in the pathogenesis of SpA 
[2, 3]. IL-23 is mainly secreted by dendritic cells and 
macrophages and acts on various innate and adaptive 
immune cells to release cytokines, including IL-17, TNF-
α, and IL-22, in target tissues, thus leading to synovitis, 
enthesitis, gut inflammation, and osteoproliferation [2]. 
IL-17 levels are elevated in the serum and synovial fluids 
of patients with SpA [4, 5]. In addition, patients with SpA 
show increased number of type 17 helper T (Th17) cells 
in the peripheral blood [6, 7]. A study on a mouse model 
of SpA indicated that IL-17 was involved in the develop-
ment of enthesitis and ileitis [8]. Recent clinical trials on 
the treatment of AS and PsA with anti-IL-17 monoclonal 
antibodies (Abs) have provided promising results [9, 10].
Th17 and regulatory T (Treg) cells exert opposite 
effects on the pathogenesis of autoimmune diseases. 
An imbalance in the number of Th17 and Treg cells 
(increased number of Th17 cells and decreased num-
ber of Treg cells) is suggested to be associated with the 
pathogenesis of SpA [6, 11–13]. Xueyi et  al. [14] sug-
gested that TNF-α-blocking agents exerted beneficial 
effects in patients with AS by suppressing TNF-α and 
by regulating Th17/Treg cell imbalance. These findings 
support the hypothesis that Th17/Treg cell imbalance is 
involved in the pathogenesis of SpA.
Rebamipide is widely used as a gastroprotective agent. 
In addition, it exerts antioxidant effects and inhibits sig-
nal transducer and activator of transcription 3 (STAT3) 
[15]. Rebamipide exerted beneficial effects in a mouse 
model of rheumatoid arthritis (RA) by regulating Th17/
Treg cell imbalance by modulating STAT3 and FoxP3 
expression [15].
ZAP-70W163C mutation impairs T cell receptor signal-
ing and induces the production of highly autoreactive 
T cells. Immunization of SKG ZAP-70W163C mice with 
1,3-β-glucan (curdlan) triggers the development of SpA 
features by activating dectin 1/Syk signaling pathway 
[16]. A study showed that SpA features could be trans-
ferred by CD4+ cells isolated from curdlan-immunized 
SKG ZAP-70W163C mice, indicating that adaptive immu-
nity played a crucial role in the pathogenesis of SpA [16]. 
Therefore, the aforementioned mouse model of SpA was 
found to be suitable for examining the effects of rebami-
pide on CD4+ T cells.
The present study determined whether rebamipide 
exerted beneficial effects in a mouse model of SpA. For 
this, we measured clinical score, histological score, length 
of the gut, and expression of cytokines in affected tissues. 
In addition, we determined the effects of rebamipide on 
CD4+ T cells by assessing Th17 and Treg cell populations 
in splenocytes isolated from rebamipide- and vehicle-
treated mice with SpA.
Methods
Mice
SKG mice with BALB/c background were kindly donated 
by Professor Shimon Sakaguchi (Department of Experi-
mental Immunology, World Premier International 
Immunology Frontier Research Center, Osaka Univer-
sity). These mice were maintained under specific path-
ogen-free (SPF) condition and were fed standard mouse 
chow (Ralston Purina, St Louis, MO, USA) and water ad 
libitum. All experimental procedures were assessed 
and approved by the Institutional Animal Care and Use 
Committee of the School of Medicine and the Animal 
Research Ethics Committee of the Catholic University 
of Korea (CUMC-2015-0063-01) and were conducted in 
accordance with the Laboratory Animals Welfare Act, 
Guide for the Care and Use of Laboratory Animals.
SpA induction and rebamipide treatment
Curdlan (3  mg/kg) was injected intraperitoneally (i.p) 
into SKG mice aged 8–10  weeks. The mice were then 
i.p injected with rebamipide (6  mg/kg) or vehicle 3 
times a week for 14  weeks. Clinical scores were moni-
tored weekly for prior 7 weeks and twice a week for later 
7  weeks: 0  =  no swelling or redness, 0.1 =  swelling or 
redness of the digits, 0.5 = mild swelling and/or redness 
of the wrist or ankle joints, and 1  =  severe swelling of 
larger joints [16]. Scores of affected joints were summed 
for each mouse.
Histopathological analysis
Formalin-fixed tissue samples from the peripheral joints, 
spine, colon, and small intestine were embedded in paraf-
fin, and 7-µm sections were prepared. The sections were 
dewaxed using xylene, dehydrated using an alcohol gra-
dient, and stained with hematoxylin and eosin (H&E). 
The H&E-stained sections of the peripheral joints and 
spine were scored for inflammation. Histological score of 
the peripheral joints was determined on a scale of 1–4: 
1 = few infiltrating immune cells, 2 = 1–2 small patches 
of inflammation, 3 = inflammation throughout the ankle 
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joint, and 4 =  inflammation in the soft tissue (enthesitis 
or fasciitis). Histological score of the spine was deter-
mined on a scale of 1–4: 1  =  few infiltrating immune 
cells, 2  =  mild inflammation of the discs or along the 
vertebrae (0–30 % of the discs), 3 = inflammation of the 
discs and/or along the vertebrae (30–70 % of the discs), 
and 4 = inflammation of 70 % of the discs and along the 
vertebrae [16].
Immunohistochemistry
Immunohistochemical analysis was performed using 
Vectastain ABC Kit (Vector Laboratories, Burlingame, 
CA, USA). The tissues were first incubated with primary 
Abs against IL-17 and TNF-α (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) overnight at 4  °C and then with 
biotinylated secondary Abs against goat (Santa Cruz Bio-
technology) and streptavidin–peroxidase complex (Vec-
tor Laboratories, Burlingame, CA, USA) for 1  h. The 
final colored product was developed using a chromogen 
3,3-diaminobenzidine (Dako, Carpinteria, CA, USA). 
All histological assessments were performed by two 
independent, blinded observers. Images were captured 
using DP71 digital camera (Olympus, Center Valley, PA, 
USA) attached to BX41 microscope (Olympus) at 3400 
magnification.
Confocal microscopy
Spleen tissues were isolated from mice in both the group 
at 14 weeks after curdlan injection. To examine the pop-
ulations of Th17 and Treg cells, the tissues were stained 
with Abs against CD4–fluorescein isothiocyanate (FITC), 
IL-17–phycoerythrin (PE), CD25–allophycocyanin, and 
FOXP3–PE (all from eBioscience, San Diego, CA, USA). 
To determine the population of cells expressing STAT, 
the tissues were stained with Abs against CD4–FITC, 
p-STAT3–Y705–PE, and p-STAT3–S727–PE (eBiosci-
ence, San Diego, CA, USA). The stained tissue sections 
were analyzed using a confocal microscope (LSM 510 
Meta; Carl Zeiss, Oberkochen, Germany). We counted 
cell number using Pannoramic MIDI and Pannoramic 
viewer (3D HISTECH Ltd, Hungary).
Flow cytometric analyses
Cell pellets were prepared from the spleen tissues iso-
lated from rebamipide- and vehicle-treated mice with 
SpA. Populations of T cells were examined by staining 
the tissues with a monoclonal Ab against CD4–peridin 
chlorophyll protein (eBioscience). Cells were permeabi-
lized and fixed with CytoFix (BD Biosciences, San Jose, 
CA, USA), as instructed by the manufacturer, and were 
stained with Abs against IL-17–PE and IL-10–FITC 
(eBioscience).
Statistical analysis
All data are expressed as mean ± SEM. Statistical analysis 
was performed using SPSS 20.0 for Windows (IBM Corp., 
Armonk, NY, USA). Differences between the two groups 
were analyzed using Mann–Whitney test by assuming 
equal variances. P < 0.05 was considered significant.
Results
Rebamipide prevents peripheral arthritis in mice with SpA
We investigated whether rebamipide prevented periph-
eral arthritis in the mouse model of SpA. Mice with 
SpA were i.p injected with rebamipide (6  mg/kg) or 
vehicle 3 times a week after curdlan injection. The mice 
were sacrificed at 14  weeks after curdlan injection and 
their joint tissues were isolated (n =  5 for each group). 
Clinical scores of rebamipide-treated mice were signifi-
cantly lower than those of vehicle-treated mice (Fig. 1a, 
1.8 ± 0.12 vs. 3.0 ± 0.06, P = 0.007). Arthritis scores (his-
tological scores of the peripheral joints) were significantly 
decreased in rebamipide-treated mice (Fig. 1b, 0.7 ± 0.19 
vs. 2.2  ±  0.10, P  =  0.035). However, spondylitis scores 
(histological scores of the spine) were not significantly 
different between rebamipide- and vehicle-treated mice 
(Fig. 1b). These results indicated that rebamipide exerted 
a substantial preventive effect on peripheral arthritis in 
mice with SpA.
Rebamipide suppresses proinflammatory cytokine 
expression in the peripheral joints and spine of mice 
with SpA
Peripheral joint and spine tissues (n = 5 for each group) 
isolated from rebamipide- and vehicle-treated mice 
were stained with Abs against IL-17 and TNF-α. IL-17 
and TNF-α expression was suppressed in the peripheral 
joints of rebamipide-treated mice (Fig. 2a, 14.0 ± 0.30 vs. 
86.0 ± 0.64 %, P = 0.029 and 6.0 ± 0.28 vs. 95.0 ± 1.00 %, 
P = 0.029). Moreover, IL-17- and TNF-α-expressing cells 
significantly decreased in the spine tissues of rebamipide-
treated mice; however, this difference was lower than 
that observed in the peripheral joint tissues (Fig.  2b, 
7.0 ± 0.38 vs. 14.0 ± 0.32 %, P = 0.029 and 15.3 ± 0.51 
vs. 49.0 ± 1.00 %, P = 0.029). These findings were con-
sistent with the aforementioned histological scores, sug-
gesting that rebamipide more substantially suppressed 
proinflammatory cytokine expression in the peripheral 
joints than in the axial joints.
Rebamipide prevents gut inflammation in mice with SpA 
by suppressing IL‑17 and TNF‑α expression in the gut
Gut tissues were isolated in the same manner as joint 
tissues (n =  5 for each group). The total length of the 
gut of rebamipide-treated mice with SpA was the same 
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as that of naive SKG mice. However, the total length 
of the gut of vehicle-treated mice with SpA was dis-
tinctly shortened (Fig. 3a, 8.5 ± 0.23 vs. 11.0 ± 0.04 cm, 
P  =  0.035). IL-17 and TNF-α expression significantly 
decreased in tissues isolated from both the large and 
small intestines of rebamipide-treated mice (Fig.  3b, 
2.0 vs. 15.0  ±  0.36  %, P  =  0.019 and 38.0  ±  0.62 vs. 
81.0  ±  0.64  %, P  =  0.029 and 1.0 vs. 4.0  ±  0.28  %, 
P = 0.029 and 21.0 ± 0.24 vs. 71.0 ± 1.00 %, P = 0.029). 
These results indicated that rebamipide exerted gastro-




Fig. 1 Rebamipide prevents arthritis in mice with SpA. Mice were i.p. injected with rebamipide 3 times a week after SpA induction. a Mean clinical 
score was determined based on arthritis severity. b Joint and spine tissues were isolated from rebamipide‑treated and vehicle‑treated mice with 
SpA at 14 weeks after curdlan injection and were stained with H&E. Inflammation and cartilage scores are shown in the bar graphs. Data are repre‑
sented as the mean ± SEM of 3 independent experiments (*P < 0.05, **P < 0.005)
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Rebamipide reciprocally regulates Th17/Treg cell 
imbalance
Spleen tissues were isolated from vehicle- and rebami-
pide-treated mice with SpA (n  =  5 for each group). 
The number of CD4+p-STAT3(Y705)+, CD4+p-
STAT3(S727)+, and CD4+IL-17+ cells was significantly 
lower in spleen tissues isolated from rebamipide-treated 
mice than in those isolated from vehicle-treated mice 
(Fig.  4a, 7.0  ±  0.40 vs. 19.0  ±  0.36  %, P  =  0.029 and 
6.0 ± 0.32 vs. 15.3 ± 0.19 %, P = 0.026 and 11.0 ± 0.34 
vs. 24.0  ±  0.24  %, P  =  0.029). The number of 
CD4+CD25+FOXP3+ cells was significantly higher in 
spleen tissues isolated from rebamipide-treated mice 
(Fig.  4a, 26.0 ±  0.64 vs. 7.0 ±  0.32  %, P =  0.029). Flow 
cytometric analysis of splenocytes isolated from mice 
in each group showed that the number of Th17 cells 
significantly decreased while that of IL-10-expressing 
Treg cells increased in rebamipide-treated mice (Fig. 4b, 
15.3 ± 0.35 vs. 18.5 ± 0.19 %, P = 0.028 and 2.2 ± 0.02 
vs. 0.5 ± 0.02 %, P = 0.028). These results are consistent 
with those of the study that showed rebamipide recipro-
cally regulated Th17/Treg cell imbalance in the mouse 
model of RA [15].
Discussion
The present study showed that rebamipide exerted pre-
ventive effects on peripheral arthritis and gut inflamma-
tion in mice with SpA. Gross appearance and histology 
showed the definite antiarthritic effect of rebamipide 
on the peripheral joints of mice with SpA. In addition, 
rebamipide preserved the length of the gut and decreased 
the expression of proinflammatory cytokines in the gut 
tissue, indicating that it exerted beneficial effects on gut 
inflammation in mice with SpA. These beneficial effects 
could be explained by 2 mechanisms: (1) suppression 
of IL-17 and TNF-α expression in the peripheral joints 
and gut tissues and (2) regulation of Th17/Treg cell 
imbalance.
The IL-23/IL-17 axis plays a critical role in the patho-
genesis of SpA [2, 3]. Antigen-presenting cells (APCs) 
such as dendritic cells and macrophages are a major 
source of IL-23 [2]. IL-23 induces immune responses by 
affecting both innate and adaptive immune cells. Vari-
ous immune cells, including Th17 cells, are involved in 
downstream immune reactions that contribute to the 
pathogenesis of SpA [2]. However, limited information 


























































































































































Fig. 2 Rebamipide suppresses proinflammatory cytokine expression in the affected peripheral joints of mice with SpA. a and b Peripheral joint and 
spine tissues were stained with H&E and then with specific Abs against IL‑17 and TNF‑α. IL‑17‑ or TNF‑α‑positive cells are shown in the bar graphs 
(right). Data are represented as the mean ± SEM of 3 independent experiments (*P < 0.05)
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pathogenesis of SpA. Dominant IL-17-expressing cells dif-
fer depending on their location, such as myeloperoxidase-
positive neutrophils in the facet joints and c-Kit-positive 
mast cells in the synovium [17, 18]. Some studies have 
suggested that innate immune response plays a dominant 
role in the pathogenesis of SpA while some studies have 
indicated that helper T cells play a dominant in the patho-
genesis of SpA. A study on mice with curdlan-induced 
SpA indicated that SpA features could be transferred to 
mice with severe combined immunodeficiency by using 
CD4+ T cells [16]. Non-responders to anti-TNF-α therapy 
showed persistently high number of Th17 cells and low 
number of Treg cells while responders showed a regu-
lation of Th17/Treg cell imbalance [14]. Moreover, the 
number of Th17 cells in these patients was positively cor-
related with Bath ankylosing spondylitis disease activity 



























































































































































































Fig. 3 Rebamipide prevents gut inflammation in mice with SpA by suppressing IL‑17 and TNF‑α expression in the gut. a Gut length is shown in the 
bar graph. b Colon and small intestine tissues were stained with H&E and then with specific Abs against IL‑17 and TNF‑α. IL‑17‑ or TNF‑α‑positive 
cells are shown in the bar graph (right). Data are represented as the mean ± SEM of 3 independent experiments (*P < 0.05)
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index (BASDAI) and Bath ankylosing spondylitis func-
tional index (BASFI), whereas the number of Treg cells 
was negatively correlated with BASDAI and BASFI [14]. 
The main pathologic cells involved in the pathogenesis of 
SpA are still unknown; however, it is certain that CD4+ 
T cells are involved in the pathogenesis of SpA. The pre-
sent study showed that rebamipide reciprocally regulated 
Th17/Treg cell imbalance in mice with SpA. However, 
rebamipide only exerted beneficial effects on the periph-
eral joints and gut and did not prevent inflammation in 
the axial joints. These findings suggest that only Th17/
Treg cell imbalance is associated with peripheral arthritis 
and gut inflammation. However, further studies should 
be performed to elucidate the mechanism underlying the 
systemic effect of Th17/Treg cell imbalance on tissue-spe-
cific pathologic cells involved in the pathogenesis of SpA.
We observed that IL-17 and TNF-α expression 
decreased in the peripheral joints and gut (where 
rebamipide exerted beneficial effects) and in the axial 
joints. These cytokines play a major role in the develop-
ment of synovitis and gut inflammation [2]. The degree 
of decrease in IL-17 and TNF-α expression in the spine 
was lower than that in the peripheral joints, which may 
be the reason why rebamipide did not exert protective 
effects in the spine. Although rebamipide did not show 
beneficial effect on spondylitis, rebamipide is relatively 
safe drug than conventional drugs including nonsteroidal 
anti-inflammatory drug (NSAID), immunosuppressants, 
and TNF-α blocker [19]. Furthermore, rebamipide could 
ameliorate NSAID-induced gastropathy [19, 20]. There-
fore, rebamipide could be added to SpA patients without 
critical side effect while maintaining current medications.
STAT3 signaling regulates the differentiation of CD4+ 
T cells into Th17 cells [21, 22]. Rebamipide inhibited 
STAT3 and regulated Th17/Treg cell imbalance in the 
mouse model of RA [15]. In another study, rebamipide 
exerted similar effects on Th17/Treg cell imbalance in a 
mouse model of RA [23]. The present study showed that 
rebamipide regulated Th17/Treg cell imbalance in mice 
with curdlan-induced SpA by modulating the activation 
of STAT3 and FOXP3. However, future studies should be 
performed to evaluate the effect of rebamipide on new 
bone formation because rebamipide acts as a STAT3 
inhibitor. In a mouse model of collagen antibody-induced 


















































































































































































































Fig. 4 Rebamipide reciprocally regulates Th17/Treg cell imbalance. Spleen tissues were isolated from mice in each group at 14 weeks after curdlan 
injection. a The tissues were stained with specific Abs against CD4 (green), CD25 (white), IL‑17 (red), FOXP3 (green), p‑STAT3–Y705 (red), and p‑STAT3–
S727 (red). Positive cells are shown in the bar graphs. b Spleen tissues were isolated from mice in each group at 14 weeks after curdlan injection. 
Splenocytes were stained with Abs against CD4–PerCP, IL‑17–PE, and IL‑10–FITC to determine the presence of Th17 and IL‑10‑expressing Treg cells. 
Data are expressed as the mean ± SEM of 3 independent experiments (*P < 0.05)
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SpA, STAT3 activation was associated with osteoblast-
mediated new bone formation [24]. A study involving 
mice with curdlan-induced SpA used micro-CT scan to 
show that curdlan injection induced new bone formation 
at 12  weeks. However, this study did not show definite 
syndesmophytes on histological findings [16]. In the pre-
sent study, vehicle-treated mice with SpA did not show 
new bone formation on histological findings. This may 
be because of an insufficient follow-up period. Therefore, 
future studies involving longer follow-up periods should 
be performed to verify the effects of rebamipide on new 
bone formation in mice with SpA.
Conclusions
In conclusion, rebamipide exerted beneficial effects in 
the mouse model of curdlan-induced SpA. Rebamipide 
prevented the development of peripheral arthritis and 
gut inflammation and suppressed the expression of major 
pathologic cytokines such as IL-17 in the peripheral 
joints, spine, and gut. Further, rebamipide reciprocally 
regulated Th17/Treg cell imbalance. These results suggest 
that rebamipide could be used as a therapeutic agent for 
treating arthritis to SpA patients.
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